NASOPHARYNGITIS is the #17 most commonly reported adverse reaction for ADALIMUMAB, manufactured by AbbVie Inc.. There are 20,607 FDA adverse event reports linking ADALIMUMAB to NASOPHARYNGITIS. This represents approximately 1.4% of all 1,482,766 adverse event reports for this drug.
Patients taking ADALIMUMAB who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
NASOPHARYNGITIS20,607 of 1,482,766 reports
NASOPHARYNGITIS is a less commonly reported adverse event for ADALIMUMAB, but still significant enough to appear in the safety profile.
Other Side Effects of ADALIMUMAB
In addition to nasopharyngitis, the following adverse reactions have been reported for ADALIMUMAB:
NASOPHARYNGITIS has been reported as an adverse event in 20,607 FDA reports for ADALIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is NASOPHARYNGITIS with ADALIMUMAB?
NASOPHARYNGITIS accounts for approximately 1.4% of all adverse event reports for ADALIMUMAB, making it a notable side effect.
What should I do if I experience NASOPHARYNGITIS while taking ADALIMUMAB?
If you experience nasopharyngitis while taking ADALIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.